Loss of ARID1A is associated with mismatch repair defects, high mutant load, high PD-L1 expression, high MSI, and an increased number of tumor-infiltrating lymphocytes in many cancers (Caumanns et al., 2018a). This evidence concerns the gene ARID1A and cancer.